[Genetic tests for controlling treatment with antidepressants]

Area of Science:

• Pharmacogenomics
• Clinical Psychiatry
• Medical Diagnostics

Background:

• Clinical practice requires individualized antidepressant selection and dosage.
• Pharmacogenetic testing, analyzing genes like CYP2D6, CYP2C19, and ABCB1, is advertised to improve antidepressant treatment outcomes.
• Commercial tests for these genes are not covered by statutory health insurance, with costs passed directly to patients.

Purpose of the Study:

• To evaluate the claims of commercially available genetic tests for guiding antidepressant therapy.
• To determine the current recommendations for using pharmacogenetic testing in antidepressant selection.
• To compare genetic testing with established methods like therapeutic drug monitoring (TDM).

Main Methods:

• Review of available clinical trial data supporting the efficacy of CYP2D6, CYP2C19, and ABCB1 genetic tests.
• Analysis of current clinical guidelines, specifically the German S3 Guideline for unipolar depression.
• Comparison of the cost coverage and indications for genetic testing versus TDM.

Main Results:

• Claims that genetic tests can avoid antidepressant treatment failure and speed up patient response are not supported by robust clinical trials.
• Existing studies show lacking or conflicting results regarding the utility of these genetic tests.
• Therapeutic drug monitoring (TDM) is recommended for non-responsive patients and is typically covered by statutory health insurance.

Conclusions:

• Routine use of commercially available pharmacogenetic tests (CYP2D6, CYP2C19, ABCB1) for antidepressant selection is not recommended.
• Cytochrome P450 genotyping is indicated only when TDM results are unexpected and other causes are ruled out.
• Further research is needed to clarify the role of the ABCB1 gene in antidepressant treatment.